NASDAQ:MDVN - (MDVN) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$81.44
+0.30 (1.20%)
Get New (MDVN) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDVN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for (MDVN) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $81.44.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in (MDVN). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/9/2016BMO Capital MarketsReiterated RatingHoldN/A
i
9/28/2016CowenReiterated RatingHoldN/A
i
Rating by Eric Schmidt at Cowen Inc
9/28/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by john newman at Canaccord Genuity
9/14/2016SunTrust BanksReiterated RatingNeutralN/A
i
8/23/2016Maxim GroupDowngradeBuy ➝ Hold$76.00 ➝ $81.50N/A
i
Rating by jason kolbert at Maxim Group
8/23/2016Canaccord GenuityReiterated RatingBuy$70.00 ➝ $82.00N/A
i
Rating by John Newman at Canaccord Genuity
8/23/2016BMO Capital MarketsBoost Price TargetMarket Perform$67.16 ➝ $81.50N/A
i
8/23/2016Credit Suisse GroupDowngradeOutperform ➝ Neutral$81.50N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
8/23/2016Stifel NicolausDowngradeBuy ➝ HoldN/A
i
8/22/2016Maxim GroupSet Price TargetBuy$76.00N/A
i
Rating by jason kolbert at Maxim Group
8/22/2016SunTrust BanksDowngradeBuy ➝ NeutralN/A
i
8/22/2016CitigroupDowngradeBuy ➝ Neutral$73.00 ➝ $81.50N/A
i
Rating by Yigal Nochomovitz at Citigroup Inc.
8/22/2016Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$72.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
8/22/2016WedbushDowngradeOutperform ➝ Neutral$81.50N/A
i
Rating by David Nierengarten at Wedbush
8/22/2016Brean CapitalDowngradeBuy ➝ HoldN/A
i
Rating by Jonathan Aschoff at Brean Capital
8/22/2016BarclaysDowngradeOverweight ➝ Equal Weight$70.00 ➝ $81.00N/A
i
Rating by Geoff Meacham at Barclays PLC
8/13/2016Canaccord GenuityReiterated RatingBuy$70.00N/A
i
Rating by John Newman at Canaccord Genuity
8/11/2016Maxim GroupSet Price TargetBuy$76.00N/A
i
Rating by jason kolbert at Maxim Group
8/11/2016BMO Capital MarketsReiterated RatingMarket Perform$53.00N/A
i
8/10/2016SVB LeerinkSet Price TargetHold$64.00N/A
i
Rating by geoff porges at SVB Leerink LLC
8/10/2016Jefferies Financial GroupReiterated RatingHold$56.00 ➝ $60.00N/A
i
8/10/2016Credit Suisse GroupBoost Price TargetOutperform$63.00 ➝ $72.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
8/10/2016JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
i
7/29/2016WedbushReiterated RatingOutperform$66.00N/A
i
Rating by David Nierengarten at Wedbush
7/17/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
7/12/2016Credit Suisse GroupReiterated RatingBuy$63.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
7/12/2016WedbushReiterated RatingOutperform$63.00 ➝ $66.00N/A
i
Rating by David Nierengarten at Wedbush
7/7/2016BMO Capital MarketsReiterated RatingMarket Perform$50.00N/A
i
7/7/2016SVB LeerinkReiterated RatingMarket Perform$64.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
7/7/2016Jefferies Financial GroupReiterated RatingHold$56.00N/A
i
7/6/2016Credit Suisse GroupReiterated RatingOutperform$63.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
6/30/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by Geoff Porges at SVB Leerink LLC
6/26/2016CitigroupReiterated RatingBuyN/A
i
Rating by Yigal Nochomovitz at Citigroup Inc.
6/16/2016BarclaysReiterated RatingOverweight$70.00N/A
i
Rating by Geoff Meacham at Barclays PLC
6/8/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
5/9/2016BMO Capital MarketsReiterated RatingMarket Perform$47.00 ➝ $50.00N/A
i
5/9/2016Jefferies Financial GroupReiterated RatingHold$52.00 ➝ $56.00N/A
i
5/8/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
5/8/2016BarclaysReiterated RatingBuyN/A
i
Rating by Geoff Meacham at Barclays PLC
5/7/2016SVB LeerinkReiterated RatingMarket Perform$39.00 ➝ $64.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
5/7/2016Royal Bank of CanadaReiterated RatingSector Perform$40.00 ➝ $70.00N/A
i
5/7/2016Brean CapitalReiterated RatingBuy$61.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
5/6/2016BarclaysBoost Price TargetOverweight$48.00 ➝ $70.00N/A
i
5/6/2016CitigroupUpgradeNeutral ➝ Buy$37.00 ➝ $73.00N/A
i
Rating by Yigal Nochomovitz at Citigroup Inc.
5/5/2016Maxim GroupBoost Price TargetBuy$47.00 ➝ $76.00N/A
i
Rating by Jason Kolbert at Maxim Group
5/4/2016MizuhoDowngradeNeutral ➝ Underperform$150.00N/A
i
5/3/2016Credit Suisse GroupBoost Price Target$63.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
5/2/2016Jefferies Financial GroupBoost Price TargetHold$39.00 ➝ $52.00N/A
i
5/2/2016Stifel NicolausBoost Price TargetBuy$52.00 ➝ $66.00N/A
i
Rating by Joel Sendek at Stifel Nicolaus
5/1/2016Credit Suisse GroupReiterated RatingBuy$49.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
5/1/2016The Goldman Sachs GroupReiterated RatingNeutral$44.00N/A
i
Rating by Salveen Richter at The Goldman Sachs Group, Inc.
4/30/2016WedbushReiterated RatingBuyN/A
i
Rating by David Nierengarten at Wedbush
4/29/2016WedbushBoost Price TargetOutperform$47.00 ➝ $59.00N/A
i
4/28/2016CitigroupReiterated RatingHold$37.00N/A
i
Rating by Yigal Nochomovitz at Citigroup Inc.
4/25/2016SVB LeerinkReiterated RatingHold$55.00 ➝ $70.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
4/19/2016SunTrust BanksReiterated RatingBuy$56.00N/A
i
4/19/2016Canaccord GenuityUpgradeHold ➝ Buy$45.00 ➝ $70.00N/A
i
Rating by John Newman at Canaccord Genuity
4/17/2016CowenReiterated RatingHoldN/A
i
Rating by Eric Schmidt at Cowen Inc
4/11/2016BMO Capital MarketsInitiated CoverageMarket Perform$47.00N/A
i
4/10/2016SVB LeerinkReiterated RatingMarket PerformN/A
i
Rating by Geoff Porges at SVB Leerink LLC
4/6/2016Canaccord GenuityReiterated RatingHoldN/A
i
Rating by John Newman at Canaccord Genuity
4/6/2016UBS GroupReiterated RatingBuy$50.00N/A
i
Rating by Matt Roden at UBS Group AG
4/5/2016SunTrust BanksInitiated CoverageBuy$56.00N/A
i
4/4/2016BTIG ResearchReiterated RatingHoldN/A
i
Rating by Hartaj Singh at BTIG Research
4/2/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
4/1/2016Jefferies Financial GroupReiterated RatingHold$39.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
3/31/2016SVB LeerinkReiterated RatingHold$39.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
3/31/2016UBS GroupReiterated RatingBuy$50.00N/A
i
3/31/2016Credit Suisse GroupBoost Price TargetOutperform$48.00 ➝ $49.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
3/30/2016BarclaysReiterated RatingBuy$42.57N/A
i
3/30/2016The Goldman Sachs GroupInitiated CoverageNeutral$44.00N/A
i
3/29/2016Canaccord GenuityReiterated RatingHold$45.00N/A
i
Rating by John Newman at Canaccord Genuity
3/28/2016BarclaysBoost Price TargetOverweight$45.00 ➝ $48.00N/A
i
3/22/2016Canaccord GenuityDowngradeHold$45.00N/A
i
Rating by John Newman at Canaccord Genuity
3/7/2016Maxim GroupReiterated RatingBuy$47.00N/A
i
Rating by Jason Kolbert at Maxim Group
(Data available from 3/3/2016 forward)
(MDVN) logo
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.
Read More

Today's Range

Now: $81.44
$81.44
$81.44

50 Day Range

MA: N/A

52 Week Range

Now: $81.44
$26.41
$81.48

Volume

N/A

Average Volume

3,545,656 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of (MDVN)?

The following sell-side analysts have issued research reports on (MDVN) in the last year:
View the latest analyst ratings for MDVN.

What is the current price target for (MDVN)?

0 Wall Street analysts have set twelve-month price targets for (MDVN) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for (MDVN) in the next year.
View the latest price targets for MDVN.

What is the current consensus analyst rating for (MDVN)?

(MDVN) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MDVN.

What other companies compete with (MDVN)?

How do I contact (MDVN)'s investor relations team?

(MDVN)'s physical mailing address is 525 Market St Fl 36, SAN FRANCISCO, CA 94105-2747, United States. The biopharmaceutical company's listed phone number is +1-415-5433470. The official website for (MDVN) is www.medivation.com.